Increased FASN has been demonstrated in cisplatin-resistant NSCLC cells compared to its expression in parental cells; this difference in expression was deemed responsible for the increased EMT and metastatic potential of cisplatin-resistant cells. This evidence concerns the gene FASN and non-small cell lung carcinoma.